iSpecimen Inc
NASDAQ:ISPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
DFI Inc
TWSE:2397
|
TW |
|
N
|
NET Power Inc
NYSE:NPWR
|
US |
|
C
|
China Ecotourism Group Ltd
HKEX:1371
|
HK |
|
AML3D Ltd
ASX:AL3
|
AU |
iSpecimen Inc
Total Current Liabilities
iSpecimen Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
iSpecimen Inc
NASDAQ:ISPC
|
Total Current Liabilities
$5.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Total Current Liabilities
$1.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Total Current Liabilities
$96.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Total Current Liabilities
$156.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Total Current Liabilities
$476.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Total Current Liabilities
$218.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
iSpecimen Inc
Glance View
iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. The company is headquartered in Lexington, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2021-06-17. The firm designed iSpecimen Marketplace platform to transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. The Company’s marketplace platform ingests de-identified healthcare data provided by healthcare supply partners. The iSpecimen Marketplace supports the supply chain management and bioprocurement process for specimens and associated data. The Company’s platform helps with administrating and reporting function for researchers, suppliers, and internal personnel, including user and compliance management. The firm serves to biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions.
See Also
What is iSpecimen Inc's Total Current Liabilities?
Total Current Liabilities
5.8m
USD
Based on the financial report for Dec 31, 2024, iSpecimen Inc's Total Current Liabilities amounts to 5.8m USD.
What is iSpecimen Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-18%
Over the last year, the Total Current Liabilities growth was -5%. The average annual Total Current Liabilities growth rates for iSpecimen Inc have been 32% over the past three years , -18% over the past five years .